Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 USD | -1.73% | +4.80% | -67.69% |
Financials (USD)
Sales 2024 * | 278M | Sales 2025 * | 372M | Capitalization | 297M |
---|---|---|---|---|---|
Net income 2024 * | -190M | Net income 2025 * | -89M | EV / Sales 2024 * | 1.88 x |
Net Debt 2024 * | 226M | Net Debt 2025 * | 224M | EV / Sales 2025 * | 1.4 x |
P/E ratio 2024 * |
-1.47
x | P/E ratio 2025 * |
-3.21
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -1.73% | ||
1 week | +4.80% | ||
1 month | -21.33% | ||
3 months | -60.22% | ||
6 months | -58.05% | ||
Current year | -67.69% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.84 | -1.73% | 1,939,398 |
24-05-30 | 2.89 | +3.21% | 1,820,541 |
24-05-29 | 2.8 | +4.87% | 2,412,026 |
24-05-28 | 2.67 | -1.48% | 1,811,087 |
24-05-24 | 2.71 | +1.50% | 1,517,637 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.69% | 297M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- RVNC Stock